SLDB supply chain intelligence for Solid Biosciences Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Solid Biosciences Inc. (SLDB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| FA212-LLC | FA212-LLC | 92% | The Company entered into an asset purchase agreement with FA212 LLC for the purchase of certain intellectual property, including patents and assigned licenses related to a preclinical drug candidate,… |
| ICS-MAUGERI-S-P-A-SB | ICS-MAUGERI-S-P-A-SB | 90% | We paid Maugeri an upfront license fee of €1.5 million, which was recorded as research and development expense during the second quarter of 2023. |
| UNIVERSITY-OF-PENNSYLVANIA | UNIVERSITY-OF-PENNSYLVANIA | 90% | The Company also assumed from FA212 contingent development milestone payments of up to $ 4.2 million, regulatory milestone payments of up to $ 13.0 million, cumulative sales milestone payments of up … |
| UNIVERSITY-OF-WASHINGTON | UNIVERSITY-OF-WASHINGTON | 80% | In 2015, we entered into a license agreement with the University of Washington, acting through UW CoMotion, under which we obtained an exclusive, royalty-bearing, sublicensable, worldwide license und… |
| KROS | Keros Therapeutics, Inc. | 72% | Reciprocal relationship from KROS graph: nued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirement… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: s, obtain marketing approval and ultimately commercialize them. If we are unable to or experience significant delays in doing so, our business will be materia… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE g… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from SRPT g… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: f treatment with our therapeutics in relation to alternative treatments and therapies; • our ability to obtain and maintain sufficient third-party coverage an… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| INSM | Insmed Incorporated | 72% | Reciprocal relationship from INSM graph: Reciprocal relationship from SLDB graph: components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macr… |
| INSM | Insmed Incorporated | 72% | components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a s… |
| MYGN | Myriad Genetics, Inc. | 72% | tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore we will be unable to obtain patent protection for our Candidates in certain jurisdi… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from SLDB graph: tain of our in-licensed U.S. patent rights lack corresponding foreign patents or patent applications, and therefore w… |
| RARE | Ultragenyx Pharmaceutical Inc. | 72% | Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE g… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from SLDB graph: components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macr… |
| TRDA | Entrada Therapeutics, Inc. | 72% | Reciprocal relationship from TRDA graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from TRDA graph: everal risks, including disruptions in supply, price increases or late deliv… |
| CARDURION-PHARMACEUTICALS-INC | CARDURION-PHARMACEUTICALS-INC | 62% | components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of o… |
| CHEVRON-U-S-A-INC | CHEVRON-U-S-A-INC | 62% | the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can … |
| CORNER-POST-INC | CORNER-POST-INC | 62% | the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can … |
| FA212-LLC | FA212-LLC | 62% | . Recently Adopted Accounting Pronouncements In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” This ASU updates income tax disclos… |
| NATURAL-RESOURCES-DEFENSE-COUNCIL-INC | NATURAL-RESOURCES-DEFENSE-COUNCIL-INC | 62% | the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union’s requirements regarding the protection of personal information can … |
| PLAB | Photronics, Inc. | 62% | Reciprocal relationship from PLAB graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from PLAB graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from PLAB g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SLDB-DEBT | Debt stack $20.7M | 90% | Market cache reports total debt of $20.7M. |
| SLDB-DEBT-12575 | Warrants outstanding: 49.35 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SLDB-OWNER-PERCEPTIVE-ADVISORS-LLC | PERCEPTIVE ADVISORS LLC | 90% | 13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 142 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BIAF | bioAffinity Technologies, Inc. | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| ATYR | aTyr Pharma, Inc. | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| IMNM | Immunome, Inc. | 100.00 | 2 | |
| BMRN | BioMarin Pharmaceutical Inc. | 100.00 | 2 | |
| ELVN | Enliven Therapeutics, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| CALC | CalciMedica, Inc. | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| RGNX | REGENXBIO Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| ALNY | Alnylam Pharmaceuticals, Inc. | 100.00 | 2 | |
| CABA | Cabaletta Bio, Inc. | 100.00 | 2 | |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 |